UroGen Pharma Ltd (URGN) concluded trading on Wednesday at a closing price of $4.17, with 9.68 million shares of worth about $40.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.73% during that period and on May 21, 2025 the price saw a loss of about -44.69%. Currently the company’s common shares owned by public are about 46.10M shares, out of which, 38.22M shares are available for trading.
Stock saw a price change of -57.75% in past 5 days and over the past one month there was a price change of -58.51%. Year-to-date (YTD), URGN shares are showing a performance of -60.85% which decreased to -68.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.46 but also hit the highest price of $20.70 during that period. The average intraday trading volume for UroGen Pharma Ltd shares is 939.90K. The stock is currently trading -57.53% below its 20-day simple moving average (SMA20), while that difference is down -59.88% for SMA50 and it goes to -64.11% lower than SMA200.
UroGen Pharma Ltd (NASDAQ: URGN) currently have 46.10M outstanding shares and institutions hold larger chunk of about 91.88% of that.
The stock has a current market capitalization of $192.27M and its 3Y-monthly beta is at 0.46. It has posted earnings per share of -$3.18 in the same period. It has Quick Ratio of 5.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for URGN, volatility over the week remained 19.42% while standing at 11.98% over the month.
Stock’s fiscal year EPS is expected to rise by 2.09% while it is estimated to increase by 74.76% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on April 16, 2025 offering a Sector outperform rating for the stock and assigned a target price of $23 to it. Coverage by Ladenburg Thalmann stated UroGen Pharma Ltd (URGN) stock as a Buy in their note to investors on February 19, 2025, suggesting a price target of $31 for the stock. On August 22, 2024, Guggenheim Initiated their recommendations, while on February 08, 2023, Jefferies Downgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Berenberg on April 27, 2022.
